A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ During Pregnancy

Pregnancy Clinical Trial

— O-STEREO  

Official title:

A Non-interventional Multi-country Cohort Study to Assess the Safety of EVUSHELD™ (Tixagevimab/Cilgavimab) During Pregnancy

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05847140
• Other study ID #: D8850R00006
• Status: Withdrawn
• Start date: June 27, 2022
• Est. completion date: January 31, 2024

Study information

• Verified date: December 2023
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Multi-country, non-interventional cohort study.The objective of the study is to characterise the risk of pregnancy and offspring (neonatal and infant) outcomes in pregnancies with and without exposure to EVUSHELD (used as a treatment or prophylaxis) among women of child-bearing indicated for such treatment in the real-world setting, using secondary data from US, France and Canada.

Description:

This is a multi-country, non-interventional cohort study in pregnancies exposed to EVUSHELD and pregnancies unexposed to EVUSHELD among women eligible for EVUSHELD. The study will be conducted within secondary data sources (administrative claims, electronic medical records (EMR) and/or registry data). For each country, the overall study period will span 12 months prior to the country-specific EVUSHELD availability until the end of the data cut or 31 March 2027, whichever is earlier.

The study will include pregnancies in individuals eligible for EVUSHELD therapy in each country in the selected datasets, including pregnant individuals aged 18 to 49 years with a high-risk condition documented in the 12 months prior to the start of the pregnancy, defined as the first day of the last menstrual period (LMP).

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 31, 2024
• Est. primary completion date: January 31, 2024
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

• Female sex at LMP

• Age 18-49 years at LMP

• Continuous coverage/clinical activity (dependent on data source type) within the confounder ascertainment period

• LMP date falls within the LMP eligibility period

• Occurrence of at least one of the following high-risk conditions during the confounder ascertainment period

• Immunocompromised conditions:

• Cancer (active solid cancer, blood cancer, or receipt of chemotherapy, immunotherapy, or radiotherapy)

• Solid organ transplant

• HIV/AIDS

• Prolonged systemic corticosteroid use (15-20 mg of prednisone equivalents for greater than 2 weeks)

• Receipt of T or B cell depleting therapy, anti-Tumour Necrosis Factor (anti- TNF), or other immunosuppressive agents

• Receipt of stem cell transplant

• Receipt of gene cell therapy of the CAR-T cell type

• Congenital immunodeficiency, primary immune deficiencies (treatment with subcutaneous or intravenous immunoglobulins - and/or immunodeficiency diagnosis codes), severe or combined immunodeficiency (including transplanted

• Severe combined immunodeficiency [SCID] where immunoglobulin replacement is required)

• Other autoimmune conditions and immune-mediated inflammatory disorders (such as systemic lupus erythematosus, Crohn's disease, ulcerative colitis).

• Conditions that increase risk of COVID-19 disease progression

• Severe risk of COVID-19 disease progression: sickle cell disease, chronic lung disease (ie, chronic bronchitis, Chronic obstructive pulmonary disease [COPD], cystic fibrosis, emphysema with dyspnoea on exertion), chronic kidney disease, cardiovascular diseases (ie, heart failure, coronary artery disease, cardiomyopathies), moderate to severe asthma, Down syndrome, rare neurological conditions (ie, multiple sclerosis, motor neurone disease, myasthenia gravis, Huntington's disease), gestational diabetes requiring medication

• Moderate risk of COVID-19 disease progression: type I or II diabetes, obesity, chronic liver disease, congenital heart disease

Exclusion Criteria:

• Multifoetal pregnancies are defined by the presence of any International Classification of Diseases (ICD-10) diagnosis code, any position indicating presence of more than one foetus (see code list) on the hospital record throughout the pregnancy episode

• Use of in vitro fertilisation or other assisted reproductive technology in the 36 weeks prior LMP as identified by ICD-10 diagnosis code "pregnancy resulting from assisted reproductive technology" or related procedure codes indicating in vitro fertilisation (IVF) or assisted reproductive technology (ART) (see code list) on the electronic health records (EHR) or hospital claims records 36 weeks prior to LMP

Related Conditions & MeSH terms

• Pregnancy
• Pregnancy Outcome
• Pregnant Women

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
AstraZeneca	Aetion, Inc.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Risk of pregnancy outcomes potentially associated with exposure in early pregnancy and measured prior to 20 weeks gestation	Spontaneous abortion, Ectopic pregnancy	Index date to < 20 weeks of gestation
Primary	Risk of pregnancy outcomes potentially associated with exposure anytime during pregnancy and measured anytime during pregnancy	Maternal Death	Index date to end of pregnancy (Note: Maternal death outcome ascertainment period is up to 42 days after the end of pregnancy episode (EPE).)
Primary	Risk of pregnancy outcomes potentially associated with exposure anytime during pregnancy and measured after 20 weeks gestation	Preterm live birth, Stillbirth, Gestational hypertension, Pre-eclampsia, Gestational diabetes	Index date to end of pregnancy Note: For preterm birth, the outcome ascertainment period is 20 to 37 weeks of gestation
Primary	Risk of outcomes in neonates potentially associated with exposure anytime during pregnancy and measured 28 days after birth	Low birth weight, Small for gestational age, Respiratory distress syndrome in the newborn, Neonatal death	Diagnosed within 28 days of birth
Primary	Risk of outcomes in infants potentially associated with exposure anytime during pregnancy and measured within 12 months after birth	Major congenital malformations, Infant death, Failure to thrive	From birth to time of death or 12 months of age